HCP
HUMA icon

Hexagon Capital Partners’s Humacyte HUMA Stock Holding History

Hexagon Capital Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$960 – 1600
2024
Q2 		$960 Buy
+200
New +$1.04K ﹤0.01% 1271

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hexagon Capital Partners's HUMA Position: Q3 2024 in Review

Hexagon Capital Partners sold out of Humacyte (HUMA) in Q3 2024, closing a stake of 200 shares — an estimated $960 sold.

Hexagon Capital Partners first reported a position in HUMA in Q2 2024 and held it in 1 quarter. The position peaked at $960 in Q2 2024. 143 funds tracked by Wall St. Rank hold HUMA as of Q3 2024.

  • Hexagon Capital Partners reported no remaining Humacyte position as of Q3 2024 after selling out during the quarter.
  • Hexagon Capital Partners sold 200 Humacyte shares in Q3 2024, an estimated $960.
  • Hexagon Capital Partners first reported a position in Humacyte in Q2 2024 and held it in 1 quarter.
  • Hexagon Capital Partners's Humacyte position peaked at $960 in Q2 2024.
  • 143 funds tracked by Wall St. Rank held Humacyte as of Q3 2024.

Based on Hexagon Capital Partners's 13F filing for Q3 2024, filed 8 Oct 2024.